Latest news with #KhalidFakhro
Qatar Tribune
7 days ago
- Health
- Qatar Tribune
Sidra Medicine contributes to breakthrough tool for early detection of Type 1 diabetes
Tribune News Network Doha Sidra Medicine, a member of Qatar Foundation, has helped develop an artificial intelligence (AI) powered tool that predicts the risk of developing Type 1 Diabetes (T1D), enabling earlier diagnosis and more targeted care. The tool uses microRNA signals in the blood to detect early biological changes linked to the disease. Published in Nature Medicine, the study titled 'A microRNA-based dynamic risk score for type 1 diabetes' introduces a dynamic risk score based on microRNAs, which are tiny molecules in the blood that reflect changes in the body, including early stress in insulin-producing Beta cells. By analysing data from over 2,800 participants, the researchers found that these molecular signals could identify individuals at high risk of developing T1D long before symptoms appear. Dr. Ammira Akil, principal investigator at Sidra Medicine and director of the Metabolic and Mendelian Disorders Translational Programme, who designed the study, said: 'This study marks a significant advancement in the way we understand and manage autoimmune diseases like Type 1 Diabetes. By combining microRNA profiling with artificial intelligence, we have developed a predictive risk score that can help identify individuals at highest risk, optimise treatment decisions and determine when to intervene. It is a powerful example of how AI and Machine Learning are transforming precision medicine into real-world clinical impact.' Sidra Medicine's contribution to the study was led by the Mendelian and Metabolic Translational Research Programme under the Precision Genomics and Translational Omics Lab. The team played a keyrole in the early laboratory work on primary human insulin-producing cells and conducted critical analyses that helped with the development and validation of the clinical risk score. The study findings complement ongoing efforts at Sidra Medicine, including the DANNA1 cohort, a local foundational population-based registry of individuals with T1D in Qatar that underpin the upcoming national screening programme for early detection and prevention of Type 1 Diabetes. Prof. Khalid Fakhro, chief research officer and chair of the Precision Medicine Programme at Sidra Medicine, said: 'The study findings demonstrate that the microRNA-based dynamic risk score can accurately differentiate between individuals with and without Type 1 Diabetes. It also predicts who may become insulin dependent after an islet cell transplant and identifies patients likely to respond to specific therapies - insights that current clinical markers cannot provide. 'Importantly, this assessment is achievable through a simple, minimally invasive blood test, making it highly promising for routine clinical use. The study also reflects our ongoing commitment to advancing the use of artificial intelligence as a powerful tool to drive earlier diagnosis, more precise treatments, and safer outcomes for patients.' The next phase of the research will focus on validating the findings across broader and more diverse populations and assessing the integration of the dynamic risk score into clinical trials and early intervention strategies. Sidra Medicine will continue to support these efforts through its research programmes and ongoing collaborations. The groundbreaking study was made possible through a multinational collaboration involving experts from Sidra Medicine, Breakthrough T1D, the University of Western Sydney, and the PREDICT T1D Study Group.
Qatar Tribune
01-07-2025
- Health
- Qatar Tribune
Sidra Medicine joins global research on adipose tissue
Tribune News Network Doha Sidra Medicine, a member of Qatar Foundation, has contributed to a major international research study published in Nature Metabolism, titled 'Towards a consensus atlas of human and mouse adipose tissue at single cell resolution'. The study presents the first global roadmap to standardise how adipose tissue is studied at the single cell level in both humans and mice. Adipose tissue, commonly known as body fat, is increasingly understood to be a highly active organ that plays a central role in metabolism, immune regulation, and hormone signalling. The connective tissues' endocrine function regulates energy metabolism, appetite, insulin sensitivity, and inflammation. Dysfunction in this tissue has been linked to a wide range of serious health conditions, including obesity, type 2 diabetes, fatty liver disease, cardiovascular disease, and lipodystrophies. Led by the Human Cell Atlas Adipose Network, the study bridges the gap between basic research and clinical application by providing clear anatomical definitions, standardising cell-type annotations, and establishing best-practice guidelines for the production and analysis of single-cell data from adipose tissue. These advancements empower researchers to better understand an organ central to metabolism, immunity, and overall health, while also enabling precision medicine approaches for obesity, diabetes, and other metabolic conditions. Dr Luis R Saraiva, director of the Congenital Malformations Translational Research Programme at Sidra Medicine and co-lead of the study, said: 'Despite its critical role in human health, adipose tissue research has long lacked the standardised tools needed for consistent study. 'This consensus paper changes that. It gives us a shared reference that allows scientists around the world to speak the same language about how we define fat tissue, how we analyse it, and how we apply those findings. That clarity is essential if we want to move from fragmented insights to real breakthroughs in understanding and treating diseases.' Prof Khalid Fakhro, chief research officer at Sidra Medicine, said: 'This landmark study reflects Sidra Medicine's commitment to advancing research that connects fundamental biology to real world health challenges, and the active role our scientists play in global consortia advancing precision health. 'By contributing to this Human Cell Atlas effort, we are establishing a reference point that will shape the future of research for conditions like obesity, diabetes and metabolic syndrome, and impact millions of patients suffering from these and other related conditions all around the world.' The paper brings together over one hundred researchers from leading institutions worldwide, including Harvard Medical School, the University of Chicago, and the University of Southern Denmark. It also highlights the role of the Human Cell Atlas consortium; a global initiative aimed at creating comprehensive reference maps of all human cells. To read the full study, visit: Towards a consensus atlas of human and mouse adipose tissue at single-cell resolution | Nature Metabolism.
Zawya
25-06-2025
- Health
- Zawya
Msheireb Museums and Sidra Medicine host Science Café on AI in Precision Medicine
Doha, Qatar: Msheireb Museums and Sidra Medicine presented the third session of the 2025 Science Café series at Bin Jelmood House. Titled "The Promise of AI in Precision Medicine: A Healthcare Revolution in Qatar," the session brought together leading experts to explore how artificial intelligence is transforming healthcare delivery in Qatar. The Science Café session examined cutting-edge developments in AI-assisted medicine, including machine learning applications in diagnostics, personalised treatment protocols, and the ethical considerations of implementing AI in healthcare settings. Discussions highlighted Qatar's pioneering efforts in integrating AI technologies with genomic medicine and digital health solutions. Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine, said: "Qatar's investment in AI-driven precision medicine positions the country as an early adopter of global healthcare innovation. Through our ongoing efforts with disease cohorts and our collaborative research networks, Sidra Medicine is building comprehensive datasets that, when combined with AI, unlock unprecedented insights into disease mechanisms and treatment responses. This Science Café session demonstrated how these technologies are already improving patient care and will continue to transform precision medicine in the years ahead." Abdulla Al Naama, General Manager of Msheireb Museums, said: "Science Café continues to serve as a vital bridge between scientific innovation and public understanding. By hosting discussions on transformative technologies like AI in medicine, Msheireb Museums fulfils its mission of fostering dialogue about progress while maintaining our connection to humanity. These conversations are essential for ensuring that technological advancement serves the broader community." The session featured speakers and a panel session with Dr. Muneera Al-Qahtani, Senior Research Associate from Qatar Environment and Energy Research Institute; Dr. Mitch Stotland, Vice Chair of Surgery and Founder of the AI and Medicine Conference series at Sidra Medicine; Dr. Madeeha Kamal, Acting Division Chief of Adolescent Medicine at Sidra Medicine; Dr. Amr Metwally, Asst. Executive Director at Hamad Medical Corporation's Itqan Clinical Simulation and Innovation Center; and Dr. Yosra Mekki a recent graduate from Qatar University's College of Medicine. Dr Sahar Da'as, Research Manager at Sidra Medicine and founder of the Science Café series, said: "The integration of AI in precision medicine represents a paradigm shift in how we approach precision medicine and healthcare. At Sidra Medicine, we are witnessing firsthand how machine learning algorithms can analyse vast genomic datasets to predict disease patterns, optimise treatment pathways, and deliver truly personalised care. This session showcased Qatar's leadership in harnessing AI to revolutionise patient care and outcomes." Exhibitors from Vraxa, Biotech Medical, Avey and SaVest, specialising in AI, virtual reality and advanced medical technologies, were also present to showcase the latest advancements in the application of AI in healthcare and precision medicine. The 2025 Science Café series continues to align with Qatar Foundation's mission to advance knowledge and community awareness. The series provides a platform for public engagement with cutting-edge scientific developments, fostering dialogue between researchers, clinicians, and the community. About Msheireb Properties Msheireb Properties, backed by Qatar Foundation and Qatar Investment Authority, is Qatar's leading sustainable real estate developer. The company has pioneered sustainable urban development in Qatar, supporting the goals of Qatar's 2030 Vision. Its mission is to change how people think about urban living and improve their overall quality of life through innovations that encourage social interaction, respect for culture, and greater care for the environment. The signature Msheireb Downtown Doha development is one of the smartest, most sustainable city districts globally. It employs a new approach to urban planning by combining traditional methods and modern technology to preserve Qatar's environment and cultural identity. All buildings are either Gold or Platinum LEED-certified. Msheireb Downtown Doha is an integrated city that embraces modern, fully furnished residential units, a range of mixed-use and commercial buildings that offer a wide array of retail and business services, and cultural facilities. It is also the home to Msheireb Museums, Mandarin Oriental Hotel, Al Wadi Hotel - MGallery by AccorHotels, Park Hyatt Hotel, Msheireb Galleria, and Barahat Msheireb - the biggest open-air covered pedestrian square in the region. The company also developed Zulal Wellness Resort by Chiva-Som, the Middle East's first and largest wellness destination. Located in northern Qatar, the resort offers two distinct experiences: Zulal Serenity, a wellness haven for individuals and couples, and Zulal Discovery, a world-first wellness offering for families. The resort is pioneering in its integration of Traditional Arabic and Islamic Medicine (TAIM) with contemporary wellness practices. About Sidra Medicine Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases.
Zawya
18-02-2025
- Health
- Zawya
Msheireb Museums and Sidra Medicine kickstart 2025 Science Café Series
Doha, Qatar – Following a successful inaugural year, Msheireb Museums, in partnership with Sidra Medicine, conducted the first session of their 2025 Science Café Series. Titled 'Nurturing Health: Our Microbiome and AI-Driven Insights for Wellness,' the session, held on Monday, attracted a large audience at Bin Jelmood House, in Msheireb Downtown Doha. Science Café, which was jointly launched in 2024 by Msheireb Museums and Sidra Medicine, is designed to promote public understanding of healthcare innovation, research and wellness updates through accessible, and interactive dialogues. Abdulla Al Naama, General Manager of Msheireb Museums, emphasised: 'Msheireb Museums is more than a space for exhibitions, it is a platform for storytelling and social dialogue. The Science Café series allows us the opportunity to provide current perspectives on Qatar's evolving healthcare landscape, while also inspiring the public through meaningful discussions. Renewing our partnership with Sidra Medicine for another year was a natural next step and a fitting culmination of our efforts to establish Msheireb Museums as a multidisciplinary platform for dialogue. We are grateful to Sidra Medicine for their continued collaboration in making this initiative a success.' Prof. Khalid Fakhro, Chief Research Officer from Sidra Medicine, said: 'The new series of Science Café 2025 promises to be more interactive and engaging. It is thanks to our partners, Msheireb Museums, that our concept became a reality in 2024 and grew from a small community initiative, to one that has educated, informed and engaged hundreds of families and students in Qatar about science and culture. We hope that our efforts will continue to create opportunities for the community to see the initiatives and research that are shaping the future of healthcare, for the children of today and tomorrow.' The Nurturing Health session featured two presentations delivered by experts from Sidra Medicine. Dr. Souhaila Al Khodor discussed "Gut Instincts: Decoding the Hidden World Within" and provided an introduction to the human microbiome, explaining its functions and the factors that influence its composition, such as lifestyle, diet, and environment. Meanwhile, "Revolutionising Women's Wellness: AI & Precision Nutrition" by Dr. Annalisa Terranegra addressed the use of precision nutrition in improving health and managing diseases. The session covered the latest applications in the field, including wearable technology, AI-driven apps, and DNA and microbiome tests that help personalise nutritional plans and dietary interventions. The panel session, featuring both speakers, also included Ms. Sirine Abou Al Hassan, Chief Clinical Dietitian from AMAN Hospital. Dr. Sahar Da'as, Research Manager at Sidra Medicine, and founder and lead of the Science Café series, said: 'We are thrilled to bring back our popular Science Café series and to renew our partnership with Msheireb Museums. The response from the public, students and families has been very positive and also indicative of the need to bring science to the community. This year, we are focusing on topics related to AI in healthcare, community health, wellness and specialist topics. We have also taken on board audience feedback to update the Science Café 2025 series, by extending the panel sessions, allowing for more audience interaction and engagement with our experts.' The 2025 Science Café Series will feature topics such as AI in precision medicine; community health; the wellness and comprehensive care industry and rare genetic conditions. For details about Science Café and to register for future sessions, please visit About Msheireb Properties Msheireb Properties is a subsidiary of Qatar Foundation for Education, Sciences and Community Development and Qatar's leading sustainable property developer, supporting the goals of Qatar's 2030 Vision and Qatar Foundation's objectives. Its mission is to change how people think about urban living and improve their overall quality of life through innovations that encourage social interaction, respect for culture, and greater care for the environment. Its signature project, Msheireb Downtown Doha, is one of the smartest, most sustainable city districts, which employs a new approach to urban planning by combining traditional methods and modern technology to preserve Qatar's environment and cultural identity. All buildings are either Gold or Platinum LEED-certified. It is an integrated city that embraces modern, fully furnished residential units, a range of mixed-use and commercial buildings that offer a wide array of retail and business services, and cultural facilities. It is also the home to Msheireb Museums, Mandarin Oriental Hotel, Al Wadi Hotel - MGallery by AccorHotels, Park Hyatt Hotel, Msheireb Galleria, and Barahat Msheireb- the biggest open-air covered pedestrian square in the region. About Sidra Medicine Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases. To access our specialized healthcare or international patient services, including pediatric care, women's health, and rare disease treatment or to book a consultation at one of our private clinics, please call +974 40033333 or visit our website at For more information, follow us on Facebook, Instagram, X and LinkedIn
